Proof-of-concept rare cancers in drug development: The case for rhabdomyosarcoma

E. Sokolowski, C. B. Turina, K. Kikuchi, D. M. Langenau, C. Keller

    Research output: Contribution to journalReview articlepeer-review

    22 Scopus citations

    Abstract

    Rare diseases typically affect fewer than 200 000 patients annually, yet because thousands of rare diseases exist, the cumulative impact is millions of patients worldwide. Every form of childhood cancer qualifies as a rare disease - including the childhood muscle cancer, rhabdomyosarcoma (RMS). The next few years promise to be an exceptionally good era of opportunity for public-private collaboration for rare and childhood cancers. Not only do certain governmental regulation advantages exist, but these advantages are being made permanent with special incentives for pediatric orphan drug-product development. Coupled with a growing understanding of sarcoma tumor biology, synergy with pharmaceutical muscle disease drug-development programs, and emerging publically available preclinical and clinical tools, the outlook for academic-community-industry partnerships in RMS drug development looks promising.

    Original languageEnglish (US)
    Pages (from-to)1877-1889
    Number of pages13
    JournalOncogene
    Volume33
    Issue number15
    DOIs
    StatePublished - Apr 10 2014

    Keywords

    • biomarker
    • drug development
    • kinase
    • proof-of-concept disease
    • rare cancers
    • rhabdomyosarcoma

    ASJC Scopus subject areas

    • Molecular Biology
    • Genetics
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Proof-of-concept rare cancers in drug development: The case for rhabdomyosarcoma'. Together they form a unique fingerprint.

    Cite this